RecruitingPhase 1NCT07806695

Islet Function in Gestational Diabetes

Sponsor

Mayo Clinic

Enrollment

90 participants

Start Date

Sep 1, 2026

Study Type

INTERVENTIONAL

Conditions

Gestational Diabetes Mellitus

Summary

The purpose of this research is to understand how the function of the human pancreas changes during and after pregnancy.

Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Exendin 9-39 for people with gestational diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 20 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGExendin 9-39

Exendin 9-39 will be administered during one postpartum study day as an intravenous infusion at 300 pmol/kg/min for 4 hours, beginning 60 minutes before the graded glucose infusion and continuing through the end of the 180-minute glucose infusion study period